Literature DB >> 18424629

Transmural distribution of metabolic abnormalities and glycolytic activity during dobutamine-induced demand ischemia.

Mohammad N Jameel1, Xiaohong Wang, Marcel H J Eijgelshoven, Abdul Mansoor, Jianyi Zhang.   

Abstract

The heterogeneity across the left ventricular wall is characterized by higher rates of oxygen consumption, systolic thickening fraction, myocardial perfusion, and lower energetic state in the subendocardial layers (ENDO). During dobutamine stimulation-induced demand ischemia, the transmural distribution of energy demand and metabolic markers of ischemia are not known. In this study, hemodynamics, transmural high-energy phosphate (HEP), 2-deoxyglucose-6-phosphate (2-DGP) levels, and myocardial blood flow (MBF) were determined under basal conditions, during dobutamine infusion (DOB: 20 microg x kg(-1) x min(-1) iv), and during coronary stenosis + DOB + 2-deoxyglucose (2-DG) infusion. DOB increased rate pressure products (RPP) and MBF significantly without affecting the subendocardial-to-subepicardial blood flow ratio (ENDO/EPI) or HEP levels. During coronary stenosis + DOB + 2-DG infusion, RPP, ischemic zone (IZ) MBF, and ENDO/EPI decreased significantly. The IZ ratio of creatine phosphate-to-ATP decreased significantly [2.30 +/- 0.14, 2.06 +/- 0.13, and 2.04 +/- 0.11 to 1.77 +/- 0.12, 1.70 +/- 0.11, and 1.72 +/- 0.12 for EPI, midmyocardial (MID), and ENDO, respectively], and 2-DGP accumulated in all layers, as evidenced by the 2-DGP/PCr (0.55 +/- 0.12, 0.52 +/- 0.10, and 0.37 +/- 0.08 for EPI, MID, and ENDO, respectively; P < 0.05, EPI > ENDO). In the IZ the wet weight-to-dry weight ratio was significantly increased compared with the normal zone (5.9 +/- 0.5 vs. 4.4 +/- 0.4; P < 0.05). Thus, in the stenotic perfused bed, during dobutamine-induced high cardiac work state, despite higher blood flow, the subepicardial layers showed the greater metabolic changes characterized by a shift toward higher carbohydrate metabolism, suggesting that a homeostatic response to high-cardiac work state is characterized by more glucose utilization in energy metabolism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18424629      PMCID: PMC2614109          DOI: 10.1152/ajpheart.01383.2007

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  35 in total

1.  Mitochondrial preference for short chain fatty acid oxidation during coronary artery constriction.

Authors:  E Douglas Lewandowski; Raymond K Kudej; Lawrence T White; J Michael O'Donnell; Stephen F Vatner
Journal:  Circulation       Date:  2002-01-22       Impact factor: 29.690

2.  An efficient MR phosphorous spectroscopic localization technique for studying ischemic heart.

Authors:  H Liu; J Zhang
Journal:  J Magn Reson Imaging       Date:  1999-11       Impact factor: 4.813

3.  Transmural gradients of glycolytic enzyme activities in left ventricular myocardium. I. The normal state.

Authors:  P Lundsgaard-hansen; C Meyer; H Riedwyl
Journal:  Pflugers Arch Gesamte Physiol Menschen Tiere       Date:  1967

4.  Importance of glycolytically derived ATP for Na+ loading via Na+/H+ exchange during metabolic inhibition in guinea pig ventricular myocytes.

Authors:  H Satoh; S Sugiyama; N Nomura; H Terada; H Hayashi
Journal:  Clin Sci (Lond)       Date:  2001-09       Impact factor: 6.124

5.  Glycogen concentration in working and nonworking ventricles of isolated dog hearts.

Authors:  L A Jedeikin; N M Buckley
Journal:  Circ Res       Date:  1967-05       Impact factor: 17.367

6.  Transmural metabolic heterogeneity at high cardiac work states.

Authors:  G Gong; K Uğurbil; J Zhang
Journal:  Am J Physiol       Date:  1999-07

7.  Increased nonoxidative glycolysis despite continued fatty acid uptake during demand-induced myocardial ischemia.

Authors:  Margaret P Chandler; Hazel Huang; Tracy A McElfresh; William C Stanley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-05       Impact factor: 4.733

8.  Myocardial oxygenation and high-energy phosphate levels during graded coronary hypoperfusion.

Authors:  J Zhang; K Ugurbil; A H From; R J Bache
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-01       Impact factor: 4.733

Review 9.  Cardiac energetics during ischaemia and the rationale for metabolic interventions.

Authors:  W C Stanley
Journal:  Coron Artery Dis       Date:  2001-02       Impact factor: 1.439

10.  Limited transfer of cytosolic NADH into mitochondria at high cardiac workload.

Authors:  J Michael O'Donnell; Raymond K Kudej; Kathyrn F LaNoue; Stephen F Vatner; E Douglas Lewandowski
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-01-29       Impact factor: 4.733

View more
  4 in total

Review 1.  PET imaging of cardiac hypoxia: opportunities and challenges.

Authors:  M G Handley; R A Medina; E Nagel; P J Blower; R Southworth
Journal:  J Mol Cell Cardiol       Date:  2011-07-14       Impact factor: 5.000

2.  Myocardial blood volume is associated with myocardial oxygen consumption: an experimental study with cardiac magnetic resonance in a canine model.

Authors:  Kyle S McCommis; Haosen Zhang; Thomas A Goldstein; Bernd Misselwitz; Dana R Abendschein; Robert J Gropler; Jie Zheng
Journal:  JACC Cardiovasc Imaging       Date:  2009-11

3.  Pressure overload-induced mild cardiac hypertrophy reduces left ventricular transmural differences in mitochondrial respiratory chain activity and increases oxidative stress.

Authors:  Michel Kindo; Sébastien Gerelli; Jamal Bouitbir; Anne-Laure Charles; Joffrey Zoll; Tam Hoang Minh; Laurent Monassier; Fabrice Favret; François Piquard; Bernard Geny
Journal:  Front Physiol       Date:  2012-08-28       Impact factor: 4.566

4.  Evaluation of left ventricular function by treadmill exercise stress echocardiography combined with layer-specific strain technique in essential hypertension patients.

Authors:  Zhang Qingfeng; Wang Yi; Li Wenhua; Zhang Hongmei; Ding Geqi; Liu Xuebing; Li Chunmei; Deng Yan; Yin Lixue
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-02-21       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.